Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Fox

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of the American College of Cardiology|July 31, 2007
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trialJacqueline Saw, Danielle M Brennan, Steven R Steinhubl, et al.
European Heart Journal|February 10, 2009
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trialsEva Swahn, Joakim Alfredsson, Rizwan Afzal, et al.
European Journal of Medicinal Chemistry|September 6, 2012
Design, synthesis and antibacterial activity of minor groove binders: the role of non-cationic tail groupsAbedawn I Khalaf, Claire Bourdin, David Breen, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 14, 2018
Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registryRong Bing, Shaun G Goodman, Andrew T Yan, et al.
American Heart Journal|March 31, 2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)C Michael Gibson, Roxana Mehran, Christoph Bode, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 13, 2009
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndromeLisa M Mielniczuk, Marc A Pfeffer, Eldrin F Lewis, et al.
JAMA Cardiology|December 9, 2020
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical TrialDerek P Chew, Karice Hyun, Erin Morton, et al.
BMJ (Clinical Research Ed.)|June 14, 2023
Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trialChris P Gale, Deborah D Stocken, Suleman Aktaa, et al.
European Heart Journal|August 1, 2014
The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart StudyAllison C Morton, Alexander M K Rothman, John P Greenwood, et al.
Indian Heart Journal|October 4, 2005
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2Dorairaj Prabhakaran, Salim Yusuf, Shamir Mehta, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of the American College of Cardiology|July 31, 2007
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trialJacqueline Saw, Danielle M Brennan, Steven R Steinhubl, et al.
European Heart Journal|February 10, 2009
Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trialsEva Swahn, Joakim Alfredsson, Rizwan Afzal, et al.
European Journal of Medicinal Chemistry|September 6, 2012
Design, synthesis and antibacterial activity of minor groove binders: the role of non-cationic tail groupsAbedawn I Khalaf, Claire Bourdin, David Breen, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 14, 2018
Use of clinical risk stratification in non-ST elevation acute coronary syndromes: an analysis from the CONCORDANCE registryRong Bing, Shaun G Goodman, Andrew T Yan, et al.
American Heart Journal|March 31, 2015
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)C Michael Gibson, Roxana Mehran, Christoph Bode, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 13, 2009
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndromeLisa M Mielniczuk, Marc A Pfeffer, Eldrin F Lewis, et al.
JAMA Cardiology|December 9, 2020
Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical TrialDerek P Chew, Karice Hyun, Erin Morton, et al.
BMJ (Clinical Research Ed.)|June 14, 2023
Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trialChris P Gale, Deborah D Stocken, Suleman Aktaa, et al.
European Heart Journal|August 1, 2014
The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart StudyAllison C Morton, Alexander M K Rothman, John P Greenwood, et al.
Indian Heart Journal|October 4, 2005
Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2Dorairaj Prabhakaran, Salim Yusuf, Shamir Mehta, et al.
Pageof 3